anti-Natriuretic Peptide A (NPPA) Antibodies

Rainbow Trout (Oncorhynchus mykiss) Natriuretic Peptide A (NPPA) interaction partners

1. Expression of atrial natriuretic peptide, C-type natriuretic peptide-1, and the guanylyl cyclase-linked (GC) natriuretic peptide receptor-A (show NPR1 Antibodies) and -B-type receptors was determined by PCR from the mRNA of head kidney leucocytes

Pig (Porcine) Natriuretic Peptide A (NPPA) interaction partners

1. Atrial natriuretic peptide and vasopressin (show AVP Antibodies)-presence in the ciliary body of eye in the pig (sus domesticus).

2. ANP and BNP (show BNC2 Antibodies) gene expression differs considerably between cardiac chambers in the first 72 hours of life in healthy piglets, resembling the transition from fetal to neonate circulation. The cardiac gene expression does not explain plasma concentrations.

3. Up-regulation of ANP and a reduction in a ratio of sarcoplasmic reticulum calcium ATPase (show CA-P60A Antibodies) 2a and phospholamban (show PLN Antibodies) in failing myocardium are observed in a porcine model of tachycardia.

4. Arial natriuretic factor (ANF (show HESX1 Antibodies)) and N-terminal proANF may be better suited than brain natriuretic peptide (show BNP Antibodies) as markers of cardiac preload during the development and treatment of acute heart failure.

5. Stimulation of prepubertal granulosa cells with FSH (show BRD2 Antibodies) resulted in a moderate expression of ANP. When FSH (show BRD2 Antibodies) treatment was followed by LH, the pronounced expression of ANP was observed in all cells.

Horse (Equine) Natriuretic Peptide A (NPPA) interaction partners

1. ANP in plasma is increased in horses with heart disease associated with altered left-sided chamber dimensions and/or function.

2. Cardiac ANP was increased in horses with mitral regurgitation (MR) and cardiac troponin levels were low in healthy and MR affected horses.

Human Natriuretic Peptide A (NPPA) interaction partners

1. Data indicate the blood pressure-lowering effect of atrial natriuretic peptide (ANP) in the general population.

2. An increase in year-by-year BP variability over the past 6 years is associated with elevated plasma levels of ANP and BNP (show BNC2 Antibodies) in the Japanese general population.

3. In summary, there were no significant differences in ANP and BNP (show BNC2 Antibodies) levels after percutaneous epicardial left atrial appendage suture ligation using LARIAT device 3 months after procedure.

4. NPPA SNPs were not associated with insulin (show INS Antibodies) resistance in older adults.

5. TIMP-4 (show TIMP4 Antibodies), NT-proANP, NT-proBNP were strongest associated with PAF (show PAF Antibodies) and AHRE (show AHR Antibodies). The discriminatory performance of CHADS2-VASc for PAF (show PAF Antibodies) was increased by addition of selected biomarkers.

6. ANP inhibits TGF-beta1 (show TGFB1 Antibodies)-induced EMT (show ITK Antibodies) in 16HBE-14o and A549 cells through cGMP/PKG (show PRKG1 Antibodies) signaling, by which it targets TGF-beta1 (show TGFB1 Antibodies)/Smad3 (show SMAD3 Antibodies) via attenuating phosphorylation of Smad3 (show SMAD3 Antibodies). These findings suggest the potential of ANP in the treatment on pulmonary diseases with airway remodeling.

7. the ANP T1766C gene polymorphism may be associated with the risk of essential hypertension, and the 1766C allele may be a protective factor against the disease

8. Corin (show CORIN Antibodies) and atrial natriuretic peptide A were most abundant in the proximal convoluted tubules and the medullary connecting ducts.

9. Higher levels of PCT (show UROD Antibodies), a marker of infection, and MRproANP, a marker for hemodynamic stress, were independently associated with ischemic stroke risk. PCT (show UROD Antibodies) was specifically associated with small vessel and MRproANP with cardioembolic stroke risk.

10. The present results demonstrate that C2238/ANP-minor allele carrier status is an independent risk factor for acute coronary syndromes recurrence in an Italian cohort of ischemic heart disease patients over the long term, and they support the role of C2238/ANP-minor allele as a negative prognostic factor in coronary artery disease patients.

Cow (Bovine) Natriuretic Peptide A (NPPA) interaction partners

1. ANP acts as an anti-permeability factor by inhibiting the signaling functions of vascular permeability factor (show VEGFA Antibodies) and by preserving the endothelial cell tight junctions functional morphology

Rabbit Natriuretic Peptide A (NPPA) interaction partners

1. These studies support the therapeutic potential of dual inhibition of NEP (show MME Antibodies) and ACE (show ACE Antibodies) in the prevention of increased arterial ECP (show ECP Antibodies) and atherogenesis which may be linked to the ANP/cGMP system.

2. Diabetes may modify the vascular actions of ANP in isolated rabbit carotid arteries and the mechanisms involved in these actions; ANP induces relaxation of precontracted carotid arteries, which is lower in diabetic than in control rabbits.

3. The study suggests that Beta1-adrenergic receptor activation decreases atrial natriuretic peptide release via cAMP- and Ca(2 (show CA2 Antibodies)+)-dependent mechanisms.

Mouse (Murine) Natriuretic Peptide A (NPPA) interaction partners

1. The present study provides a novel insight into the potential underlying mechanisms of telmisartan-induced inhibition of cardiomyocyte hypertrophy, which involves inhibition of NFAT (show NFATC1 Antibodies) activation, nuclear translocation and the ANP/BNP (show BNC2 Antibodies) cascade.

2. we investigated pregnancies of ANP wild type, heterozygous, and knockout mice. Maternal blood pressure did not differ between genotypes, and fetal weight was unaffected. Placental weight was greater in ANP(-/-) versus ANP(+/+) mice. Therefore, in our hands, the ANP model does not express phenotypic features of preeclampsia with fetal growth restriction.

3. Data (including data from studies in knockout mice) suggest expression of ANP/BNP (show BNC2 Antibodies)/GC-A (show GUCA1A Antibodies) (atrial natriuretic peptide, brain natriuretic peptide (show BNP Antibodies), and guanylyl cyclase-A (show NPR1 Antibodies)) is important in embryonic neovascularization and organogenesis.

4. Goalpha plays a role in ANF (show HESX1 Antibodies) sorting during intracellular vectorial transport and with the presence of a mechanism that preserves the molar relationship between cellular ANF (show HESX1 Antibodies) and BNP (show BNC2 Antibodies).

5. ANP prevents cancer metastasis by inhibiting the adhesion of tumor cells to inflamed endothelial cells

6. Expression of NPPA splice variants is differentially regulated in the developing mouse heart.

7. NPPA acts on the NPR1 receptor, is expressed in mouse dorsal root and trigeminal ganglia, and the spinal cord.

8. Natriuretic peptides buffer renin (show REN Antibodies)-dependent hypertension.

9. Data indicate that the identified stress-responsive enhancer of Nppa and Nppb (show BNP Antibodies), the most common markers of heart failure, is a 650-bp fragment within 50 kb of the Nppa and Nppb (show BNP Antibodies) loci.

10. Absence of maternal atrial natriuretic peptide leads to gestational hypertension and adaptive changes fetal cardiac growth and blood pressure regulation.